Dr. Frank Hensel
Dr. Frank Hensel is Principal at the High-Tech Gründerfonds (HTGF) and an expert in the early stage financing of life science start-ups. Frank joined the HTGF in 2015 and successfully managed the investments in several early stage biotech companies. He is an active Board member and holds Board Observer positions in several life science companies developing novel (anti-cancer) therapeutics and medical devices.
In 2001, Frank became CEO and Co-Founder of OncoMab GmbH, a spin-off of the University of Würzburg’s Institute of Pathology, where he was involved in several milestone achievements regarding product and business development as well as the company’s transition to the Australian stock exchange. He studied Biophysics at University Osnabrück and holds a PhD in the area of tumor-reactive antibodies from the Ludwig Maximilians University of Würzburg.